SENSEX
NIFTY
GOLD
USD/INR

Weather

image 8    C

Business News

The Economic Times

Business / The Economic Times

details

Piramal Pharma Q3 Results: Co reports loss as CDMO slowdown drags revenue

Piramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and regulatory delays. Management sees recovery signs, cost controls cushioning EBITDA, and expects a stronger Q4.

29 Jan 2026 6:11 pm